crinetics.png
Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
November 08, 2021 08:00 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 16:02 ET | Crinetics Pharmaceuticals, Inc.
– Commenced dosing in Phase 3 PATHFNDR-1 study – – Phase 1 single-ascending dose data demonstrate the dose-dependent and clinically-significant pharmacodynamic effects of CRN04894 – – Phase 1 data...
crinetics.png
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
June 28, 2021 07:30 ET | Crinetics Pharmaceuticals, Inc.
- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a...
crinetics.png
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:05 ET | Crinetics Pharmaceuticals, Inc.
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics...
crinetics.png
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
April 12, 2021 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 07, 2021 18:31 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 16:05 ET | Crinetics Pharmaceuticals, Inc.
Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively ...
crinetics.png
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
November 16, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 06, 2020 08:31 ET | Crinetics Pharmaceuticals, Inc.
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly CRN04777 received Rare Pediatric Disease Designation for the...
crinetics.png
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
October 26, 2020 07:02 ET | Crinetics Pharmaceuticals, Inc.
ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy   Paltusotine was observed to be well tolerated among...